Cempra drug is effective, safe for bacterial pneumonia in trial

09/15/2011 | MedCityNews.com

A midstage trial found that Cempra Pharmaceuticals' drug candidate solithromycin is as effective as FDA-approved antibiotic levofloxacin in treating community-acquired bacterial pneumonia, but with less risk of adverse effects. The result supports further evaluation of solithromycin in a Phase III test, said Cempra official David Oldach. The drug is also expected to work against sexually transmitted diseases and Legionnaires' disease.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA